Durable Remission Achieved from Bcma-Directed CAR-T Therapy Against Relapsed or Refractory Multiple Myeloma

Conclusions: Our result demonstrates the high potential of this single CAR-T infusion therapy for RRMM, including 3 sCRs and ongoing durable clinical responses, with only mild and manageable CRS to date. These initial data provide strong evidence to support the further development of this anti-myeloma cellular immunotherapy.DisclosuresLiu: HRAIN Biotechnology: Employment. Fang: HRAIN Biotechnology: Employment. He: HRAIN Biotechnology: Employment. Xie: HRAIN Biotechnology: Employment. Chen: HRAIN Biotechnology: Employment. Wei: HRAIN Biotechnology: Employment. Tao: HRAIN Biotechnology: Employment. Wang: Immune Design: Equity Ownership; HRAIN Biotechnology: Consultancy, Equity Ownership.

Source: Blood - November 21, 2018 Category: Hematology Authors: Liu, Y., Chen, Z., Fang, H., Wei, R., Yu, K., Jiang, S., Fu, W., Jiang, H., Du, J., He, F., Xie, R., Chen, J., Wei, B., Tao, J., Wang, P. Tags: 653. Myeloma: Therapy, excluding Transplantation: Immunotherapies in Plasma Cell Disorders Source Type: research